Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587288 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
A Phase 2 study, sponsored by Ception Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00587288: Completed Phase 2 study, sponsored by Ception Therapeutics.
NCT00587288 is a Phase 2 study that has completed, run by Ception Therapeutics. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587288, a Phase 2 study, has completed, sponsored by Ception Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
Primary Outcome
The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, and 6. Each increasing value is an indication of poorer asthma control. At protocol specified visits, the participant answered questions 1 to 6, circling the response that best described how that participant was during the past week, on the basis of a daily diary for the week before the visit. At the actual visit, study center personnel reviewed the questions and responses with the participant and deter
Interventions
- OTHER Saline
- BIOLOGICAL Reslizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00587288 record still lists
NCT00587288 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00587288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00587288 about?
NCT00587288 is a clinical study titled "Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma". The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
What is the current status of trial NCT00587288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2008-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00587288?
The interventions under investigation include: Saline (OTHER), Reslizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00587288?
This trial is sponsored by Ception Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00587288's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia